|
JP5588175B2
(ja)
|
2006-11-07 |
2014-09-10 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｐｃｓｋ９のアンタゴニスト
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
MX2011000117A
(es)
*
|
2008-07-10 |
2011-02-25 |
Toray Industries |
Composicion farmaceutica para tratamiento y prevencion de cancer.
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
ES2670576T3
(es)
*
|
2009-09-03 |
2018-05-31 |
Pfizer Vaccines Llc |
Vacuna de PCSK9
|
|
IN2012DN03824A
(enExample)
|
2009-10-30 |
2015-08-28 |
Merck Sharp & Dohme |
|
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
EP3424949A1
(en)
*
|
2010-04-13 |
2019-01-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind pcsk9
|
|
SG185487A1
(en)
|
2010-05-11 |
2012-12-28 |
Aveo Pharmaceuticals Inc |
Anti-fgfr2 antibodies
|
|
GB2481373A
(en)
*
|
2010-06-21 |
2011-12-28 |
Weiming Xu |
Treatment of hypercholesterolaemia by ubiquitination of PCSK9
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
WO2012088313A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
HRP20180959T1
(hr)
*
|
2011-01-28 |
2018-07-27 |
Sanofi Biotechnology |
Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
|
|
HK1202804A1
(en)
*
|
2011-07-14 |
2015-10-09 |
辉瑞公司 |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
CA2848201C
(en)
*
|
2011-09-16 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
|
HK1204477A1
(en)
*
|
2011-12-20 |
2015-11-20 |
阿达拉塔合伙有限公司 |
Single domain antibodies as inhibitors of pcsk9
|
|
CA2865644A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
KR102213535B1
(ko)
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
EP3348140B1
(en)
|
2012-03-16 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
RU2015101113A
(ru)
*
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
|
NZ704771A
(en)
|
2012-08-13 |
2018-02-23 |
Regeneron Pharma |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
EP3072548B1
(en)
|
2012-11-21 |
2019-03-06 |
Amgen, Inc |
Drug delivery device
|
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
|
US10492990B2
(en)
|
2013-03-15 |
2019-12-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
CN111617347B
(zh)
|
2013-03-15 |
2023-09-29 |
安进公司 |
身体轮廓可调适的自动注射器装置
|
|
JP2016514668A
(ja)
*
|
2013-03-15 |
2016-05-23 |
アムジエン・インコーポレーテツド |
プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質
|
|
EP2976117B1
(en)
|
2013-03-22 |
2020-12-30 |
Amgen Inc. |
Injector and method of assembly
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
CN111920954A
(zh)
|
2013-06-07 |
2020-11-13 |
再生元制药公司 |
通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
|
|
AU2013396206B2
(en)
|
2013-06-28 |
2019-11-14 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
US10035847B2
(en)
|
2013-10-02 |
2018-07-31 |
The Rockefeller University |
Amyloid protofibril antibodies and methods of use thereof
|
|
SG11201602876WA
(en)
|
2013-10-24 |
2016-05-30 |
Amgen Inc |
Injector and method of assembly
|
|
WO2015061389A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
CN106062003A
(zh)
|
2013-11-12 |
2016-10-26 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
EP3076994A4
(en)
*
|
2013-12-06 |
2017-06-07 |
Modernatx, Inc. |
Targeted adaptive vaccines
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
SG10201811702TA
(en)
|
2014-05-07 |
2019-01-30 |
Amgen Inc |
Autoinjector with shock reducing elements
|
|
MX387194B
(es)
|
2014-06-03 |
2025-03-18 |
Amgen Inc |
Sistemas y metodos para procesar de manera remota datos recolectados por un dispositivo de suministro de farmaco.
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
EP2975059A1
(en)
|
2014-07-15 |
2016-01-20 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
DE202015009006U1
(de)
|
2014-07-15 |
2016-08-19 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
KR20170029613A
(ko)
|
2014-07-16 |
2017-03-15 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
US20170224816A1
(en)
|
2014-08-06 |
2017-08-10 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
EP3194441A1
(en)
|
2014-09-16 |
2017-07-26 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
US10472424B2
(en)
|
2014-09-23 |
2019-11-12 |
Pfizer Inc. |
Treatment with anti-PCSK9 antibodies
|
|
EP3943135B1
(en)
|
2014-10-14 |
2025-09-24 |
Amgen Inc. |
Drug injection device with visual and audible indicators
|
|
MA54716A
(fr)
|
2014-10-23 |
2021-11-17 |
Amgen Inc |
Réduction de la viscosité de formulations pharmaceutiques
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
MA41022A
(fr)
*
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
EP3689394A1
(en)
|
2014-12-19 |
2020-08-05 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
US10799630B2
(en)
|
2014-12-19 |
2020-10-13 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
CN105461809B
(zh)
|
2015-02-11 |
2018-10-12 |
康融东方（广东）医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
|
ES2748750T3
(es)
|
2015-02-17 |
2020-03-17 |
Amgen Inc |
Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
|
|
US11806509B2
(en)
|
2015-02-27 |
2023-11-07 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
|
|
EP3271405A1
(en)
|
2015-03-20 |
2018-01-24 |
Aarhus Universitet |
Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
|
|
CN105037554B
(zh)
*
|
2015-06-12 |
2019-04-12 |
成都贝爱特生物科技有限公司 |
抗人pcsk9抗体的制备及其用途
|
|
IL314925A
(en)
|
2015-08-18 |
2024-10-01 |
Regeneron Pharma |
Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
|
CN106810609A
(zh)
*
|
2015-11-27 |
2017-06-09 |
苏州君盟生物医药科技有限公司 |
抗pcsk9抗体及其应用
|
|
US11351308B2
(en)
|
2015-12-09 |
2022-06-07 |
Amgen Inc. |
Auto-injector with signaling cap
|
|
WO2017114230A1
(zh)
*
|
2015-12-31 |
2017-07-06 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
US20200270365A1
(en)
*
|
2016-01-05 |
2020-08-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
|
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
MX2018008681A
(es)
|
2016-01-13 |
2018-09-17 |
Novo Nordisk As |
Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
|
|
EP3429663B1
(en)
|
2016-03-15 |
2020-07-15 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
|
CN107266575B
(zh)
|
2016-04-07 |
2021-12-24 |
天士力生物医药股份有限公司 |
前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
JP7309363B2
(ja)
|
2016-05-13 |
2023-07-18 |
アムジエン・インコーポレーテツド |
バイアル・スリーブ組立体
|
|
US11238150B2
(en)
|
2016-05-16 |
2022-02-01 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
WO2017205377A2
(en)
*
|
2016-05-23 |
2017-11-30 |
New York University |
Compositions and methods for antibodies targeting staphylococcal leukotoxins
|
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
CN107474140B
(zh)
*
|
2016-06-08 |
2022-06-03 |
常州博嘉生物医药科技有限公司 |
Pcsk9特异性的结合蛋白mv072及其应用
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
JP7110124B2
(ja)
*
|
2016-06-24 |
2022-08-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
心血管疾患を治療するための組成物及び方法
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
US11111313B2
(en)
|
2016-09-20 |
2021-09-07 |
WuXi Biologics Ireland Limited |
Anti-PCSK9 antibodies
|
|
US20200165354A1
(en)
*
|
2016-09-20 |
2020-05-28 |
WuXi Biologics Ireland Limited |
Novel Anti-PCSK9 Antibodies
|
|
ES2871783T3
(es)
|
2016-09-20 |
2021-11-02 |
Univ Aarhus |
Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
|
|
MA46466A
(fr)
|
2016-10-06 |
2019-08-14 |
Amgen Inc |
Formulations pharmaceutiques de protéines à viscosité réduite
|
|
EP3529278A1
(en)
|
2016-10-20 |
2019-08-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
CN108239150A
(zh)
*
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
|
MX2019008432A
(es)
|
2017-01-17 |
2019-11-18 |
Amgen Inc |
Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
|
|
MX2019009755A
(es)
|
2017-02-17 |
2019-10-07 |
Amgen Inc |
Mecanismo de insercion para dispositivo de suministro de farmacos.
|
|
US11752258B2
(en)
|
2017-02-17 |
2023-09-12 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
|
JP7377596B2
(ja)
*
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
WO2018165143A1
(en)
|
2017-03-06 |
2018-09-13 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
WO2018164829A1
(en)
|
2017-03-07 |
2018-09-13 |
Amgen Inc. |
Needle insertion by overpressure
|
|
IL268386B2
(en)
|
2017-03-09 |
2023-11-01 |
Amgen Inc |
Insertion mechanism for a drug delivery device
|
|
PL3600491T3
(pl)
|
2017-03-28 |
2024-03-04 |
Amgen Inc. |
Układ i sposób montażu trzonu tłoka i strzykawki
|
|
AU2018258676B2
(en)
|
2017-04-28 |
2024-09-19 |
Amgen Inc. |
N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
|
|
EP3634546A1
(en)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Torque driven drug delivery device
|
|
WO2018226515A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
WO2018236619A1
(en)
|
2017-06-22 |
2018-12-27 |
Amgen Inc. |
Device activation impact/shock reduction
|
|
JP7475860B2
(ja)
|
2017-06-23 |
2024-04-30 |
アムジエン・インコーポレーテツド |
スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
EP3651832B1
(en)
|
2017-07-14 |
2023-12-13 |
Amgen Inc. |
Needle insertion-retraction system having dual torsion spring system
|
|
BR112020001286A2
(pt)
|
2017-07-19 |
2020-07-28 |
Novo Nordisk A/S |
composto, e, método de tratamento da diabetes, sobrepeso e/ou doenças cardiovasculares
|
|
US11525004B2
(en)
|
2017-07-20 |
2022-12-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Recombinant CD123-binding antibodies
|
|
US11672733B2
(en)
|
2017-07-21 |
2023-06-13 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
|
JP2020528296A
(ja)
|
2017-07-25 |
2020-09-24 |
アムジエン・インコーポレーテツド |
ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
|
|
JP7242562B2
(ja)
|
2017-07-25 |
2023-03-20 |
アムジエン・インコーポレーテツド |
容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
|
|
EA202090380A1
(ru)
|
2017-08-01 |
2020-05-21 |
Эмджен Инк. |
Системы и способы для выполнения анализа гликанов в образце в режиме реального времени
|
|
EA202090399A1
(ru)
|
2017-08-01 |
2020-05-20 |
Эмджен Инк. |
Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
|
|
US12318593B2
(en)
|
2017-08-09 |
2025-06-03 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
|
EP3668567A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
US11759565B2
(en)
|
2017-10-04 |
2023-09-19 |
Amgen Inc. |
Flow adapter for drug delivery device
|
|
EP3691716B1
(en)
|
2017-10-06 |
2023-11-29 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
|
IL273323B2
(en)
|
2017-10-09 |
2024-10-01 |
Amgen Inc |
Drug delivery device with drive assembly and related assembly method
|
|
US11826480B2
(en)
|
2017-11-03 |
2023-11-28 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
|
MA50569A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Ensembles de remplissage-finition et procédés associés
|
|
MA50553A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Dispositif d'administration de médicament avec détection de positionnement et de débit
|
|
SG11202002966QA
(en)
|
2017-11-10 |
2020-05-28 |
Amgen Inc |
Plungers for drug delivery devices
|
|
AU2018368340B2
(en)
|
2017-11-16 |
2024-03-07 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
|
JP7747438B2
(ja)
|
2017-11-16 |
2025-10-01 |
アムジエン・インコーポレーテツド |
失速及び終点検出を有するオートインジェクタ
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US12110342B2
(en)
*
|
2018-01-31 |
2024-10-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
|
|
WO2019165326A1
(en)
*
|
2018-02-23 |
2019-08-29 |
REMD Biotherapeutics, Inc |
Calcitonin gene-related peptide (cgrp) antagonist antibodies
|
|
AU2019234846A1
(en)
|
2018-03-13 |
2020-09-24 |
Amgen Inc. |
Sequential digestion of polypeptides for mass spectrometric analysis
|
|
EP3765856B1
(en)
|
2018-03-13 |
2023-09-27 |
Amgen Inc. |
Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
MX2021000749A
(es)
|
2018-07-24 |
2021-03-29 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
EP3826701A1
(en)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
|
WO2020028009A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
EP3837286A4
(en)
|
2018-08-16 |
2022-08-10 |
The Johns Hopkins University |
ANTIBODIES TO HUMAN ZNT8
|
|
JP2022500095A
(ja)
|
2018-09-24 |
2022-01-04 |
アムジエン・インコーポレーテツド |
インターベンション投薬システム及び方法
|
|
IL281469B2
(en)
|
2018-09-28 |
2024-08-01 |
Amgen Inc |
Muscle wire escapement activation assembly for a drug delivery device
|
|
EP3860685A1
(en)
|
2018-10-02 |
2021-08-11 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
US12151089B2
(en)
|
2018-10-05 |
2024-11-26 |
Amgen Inc. |
Drug delivery device having dose indicator
|
|
SG11202101824VA
(en)
|
2018-10-15 |
2021-03-30 |
Amgen Inc |
Platform assembly process for drug delivery device
|
|
MA53912A
(fr)
|
2018-10-15 |
2022-01-19 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
|
|
EP3873566B1
(en)
|
2018-11-01 |
2024-11-27 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
AU2019370159B2
(en)
|
2018-11-01 |
2025-05-29 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
AU2019396614B2
(en)
|
2018-12-14 |
2025-07-10 |
Amgen Inc. |
System suitability method for use with protein concentration determination by slope
|
|
ES2987091T3
(es)
|
2019-02-14 |
2024-11-13 |
Amgen Inc |
Sistemas y métodos para preparar una muestra y realizar un ensayo en tiempo real de la muestra
|
|
AU2020226619A1
(en)
|
2019-02-20 |
2021-08-05 |
Amgen Inc. |
Methods of determining protein stability
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
US20230035363A1
(en)
|
2019-03-04 |
2023-02-02 |
Amgen Inc. |
In vivo reversibility of high molecular weight species
|
|
US12078701B2
(en)
|
2019-03-27 |
2024-09-03 |
Amgen Inc. |
Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
|
|
US20220160972A1
(en)
|
2019-04-24 |
2022-05-26 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
ES2997211T3
(en)
|
2019-06-05 |
2025-02-14 |
Amgen Inc |
Methods of identifying attributes of therapeutic proteins
|
|
JP7608439B2
(ja)
|
2019-08-23 |
2025-01-06 |
アムジエン・インコーポレーテツド |
構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
BR112022020407A2
(pt)
|
2020-04-09 |
2023-05-02 |
Verve Therapeutics Inc |
Edição base do pcsk9 e métodos de uso do mesmo para tratamento de doenças
|
|
GB202008860D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
KR20210158693A
(ko)
*
|
2020-06-24 |
2021-12-31 |
바이오스트림테크놀러지스(주) |
항 ｐｃｓｋ９ 항체 및 이의 용도
|
|
WO2022061092A1
(en)
|
2020-09-18 |
2022-03-24 |
Amgen Inc. |
Methods of processing a sample for peptide mapping analysis
|
|
WO2022098595A1
(en)
|
2020-11-05 |
2022-05-12 |
Amgen Inc. |
Materials and methods for protein processing
|
|
US20240208680A1
(en)
|
2021-05-21 |
2024-06-27 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
|
EP4387666A4
(en)
*
|
2021-08-20 |
2025-07-16 |
Univ Johns Hopkins |
CELL SURFACE ANTIBODY FOR A PANCREATIC BETA CELL SPECIFIC BIOMARKER
|
|
WO2023070103A1
(en)
|
2021-10-21 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Modulators of proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
EP4430174A1
(en)
|
2021-11-09 |
2024-09-18 |
Amgen Inc. |
Production of therapeutic proteins
|
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
|
WO2024259275A1
(en)
|
2023-06-14 |
2024-12-19 |
Bristol-Myers Squibb Company |
Near real time sialic acid quantitation of glycoproteins
|
|
WO2025101602A1
(en)
|
2023-11-07 |
2025-05-15 |
Amgen Inc. |
Methods of analyzing amino acid content of a therapeutic protein
|
|
WO2025144700A1
(en)
|
2023-12-27 |
2025-07-03 |
Absci Corporation |
Nanobody library screening using bacterial surface display
|
|
CN118791609B
(zh)
*
|
2024-09-13 |
2024-11-26 |
江苏凯基生物技术股份有限公司 |
一种抗igf-1的单克隆抗体及制备方法及试剂盒及应用
|